Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Shares Outstanding (Weighted Average) (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $58.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.77% to $58.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.7 million through Dec 2025, up 1.77% year-over-year, with the annual reading at $58.7 million for FY2025, 1.77% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $58.7 million in Q4 2025 for Voyager Therapeutics, roughly flat from $58.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $58.7 million in Q4 2025 to a low of $37.5 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $46.9 million across 5 years, with a median of $42.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 40.57% in 2024 and later increased 1.31% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $37.7 million in 2021, then grew by 1.83% to $38.4 million in 2022, then grew by 12.16% to $43.0 million in 2023, then soared by 34.05% to $57.7 million in 2024, then rose by 1.77% to $58.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for VYGR at $58.7 million in Q4 2025, $58.6 million in Q3 2025, and $58.5 million in Q2 2025.